Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

Clinical trial NCT03919539 · UNKNOWN

Trial details

NCT number: NCT03919539
Sponsor: Peking University People's Hospital
Status: UNKNOWN
Study type: OBSERVATIONAL

Drug Resistance to Famitinib and Camrelizumab Biomarkers for Efficacy and Toxicity

Start date: 2019-12-01
Primary completion: 2021-06-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.